Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

173
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
173
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

139
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
139
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

410
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
410
Drug Dependence01:17

Drug Dependence

950
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
950
Analgesia and Pain Management01:25

Analgesia and Pain Management

399
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
399
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

332
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
332

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nonclinical Time for Family Medicine Residency Faculty: National Survey Results.

PRiMER (Leawood, Kan.)·2022
Same author

Integrating Buprenorphine Treatment for Opioid Use with Primary Care is Associated with Greater Retention in Treatment.

Journal of the American Board of Family Medicine : JABFM·2022
Same author

Integrating Buprenorphine Treatment Into Family Medicine Resident Clinic.

Family medicine·2020
Same author

Depression Screening in an Academic Family Practice.

Family medicine·2017
Same author

A patient-centered telephone intervention using the asthma action plan.

Family medicine·2012
Same author

Update on acute ankle sprains.

American family physician·2012

Related Experiment Video

Updated: May 13, 2025

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.1K

Common Questions About Buprenorphine Treatment for Opioid Use Disorder.

Jeffrey D Tiemstra1

  • 1Aurora Health Care, Paddock Lake, Wisconsin.

American Family Physician
|April 16, 2025
PubMed
Summary

Buprenorphine is a safe and effective medication for opioid use disorder, showing over 50% retention at one year. It offers a lower risk of respiratory depression than methadone and should be widely prescribed.

Area of Science:

  • Addiction Medicine
  • Pharmacology

Background:

  • Opioid use disorder (OUD) is a significant public health crisis.
  • Buprenorphine is an effective medication for OUD, demonstrating high treatment retention and a favorable safety profile.
  • Compared to methadone, buprenorphine presents a substantially lower risk of respiratory depression.

Purpose of the Study:

  • To inform physicians about the efficacy and safety of buprenorphine for treating opioid use disorder.
  • To provide guidance on initiating and managing buprenorphine treatment in adult patients.
  • To emphasize buprenorphine as a long-term maintenance therapy for a chronic condition.

Main Methods:

  • Physicians should screen adult patients for OUD using validated tools.
  • Offer buprenorphine to patients with moderate to severe OUD.

More Related Videos

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

252
Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

5.2K

Related Experiment Videos

Last Updated: May 13, 2025

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.1K
Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

252
Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

5.2K
  • Titrate buprenorphine doses rapidly to manage cravings and withdrawal, typically 16-32 mg/day.
  • Schedule follow-up appointments every 1-3 months for stabilized patients.

    • Main Results:

    • Buprenorphine treatment offers a treatment retention rate exceeding 50% at one year.
    • Rapid dose titration effectively suppresses cravings and withdrawal symptoms.
    • Counseling and behavioral therapy are optional, based on patient needs, not required for treatment success.
    • Regular urine drug testing aids in identifying patients needing further support, not for termination.

    Conclusions:

    • Buprenorphine is a highly effective and safe first-line treatment for opioid use disorder.
    • Treatment should be continued long-term, as long as beneficial, for this chronic disease.
    • Extended treatment duration is associated with lower relapse rates, particularly after one year.